NPI 1881342293 — Billing Profile & Reimbursement Data
NPI 1881342293 · XX · healthcare
Customize your policy alerts
Sign up for NPI 1881342293 — Billing Profile & Reimbursement Data policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
NPI 1881342293 is a healthcare provider located in Unspecified Location. This profile covers 22 Medicare and 0 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services. Note: "XX" is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; claims coded under it are grouped and benchmarked here the same way a traditional state would be.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | NPI 1881342293 |
| Address | |
| City | |
| State | XX (Unspecified Location) |
| ZIP | |
| Taxonomy | N/A |
| NPI Enumerated | |
| NPI Deactivated | April 11, 2024 |
(source: CMS Medicare & Medicaid claims data)
Key Findings
This provider’s Medicare billing profile is concentrated in high-complexity molecular and genetic diagnostic testing: top CPT/HCPCS entries in the file include 81162 (BRCA1/BRCA2 full-sequence/deletion-duplication), 81317 (PMS2 full-sequence), and 81298 (MSH6 full-sequence), with individual code revenues such as $758.1K for 81162, $655K for 81317, and $627.7K for 81298. The presence of multiple full-gene sequencing and large-scale deletion/duplication codes indicates an operation structured around next-generation sequencing and specialty hereditary cancer and genetic disorder assays rather than routine clinical pathology services.
Revenue concentration is significant at the code level: the precomputed top 3 Medicare codes by revenue account for 33.5% of this provider's total Medicare revenue, and the single largest listed code represents $758.1K (12.5% of Medicare revenue). That degree of concentration implies a small set of specialized assays drive a material share of the $6.1M in Medicare revenue reported for this NPI.
Medicare: Total Revenue Breakdown by CPT/HCPCS Code
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
Medicare: Complete Services Breakdown
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
22 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 420 | $1,790 | $758.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 990 | $660 | $655K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 1,000 | $630 | $627.7K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 910 | $660 | $605.3K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 830 | $590 | $487.5K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 800 | $590 | $470.4K |
| 81222 | The lab analyst performs the technical lab test to analyze specific changes involving repeated or deleted nucleotides in the cystic fibrosis transmembrane conductance regulator gene, also known as… | 1,010 | $430 | $428.6K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 830 | $490 | $406.4K |
| 81300 | The lab analyst performs the technical lab test to detect genetic changes involving long sequences of deleted or duplicated DNA in the gene for mutS homolog 6 [E. coli], or MSH6 gene. | 1,140 | $230 | $266.3K |
| 81319 | The lab analyst performs the technical lab test to detect genetic changes involving long sequences of deleted or duplicated DNA in the gene for postmeiotic segregation increased 2 [S. cerevisiae], or… | 1,140 | $200 | $227.3K |
Showing 1–10 of 22
Medicare: Competitive Analysis & Benchmarks
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes. Note: this provider's state, "XX," is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; the State panel below benchmarks against other providers coded under the same designation.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Frequently Asked Questions
References
- 1.Medicare Physician & Other Practitioner by Provider and Service. CMS.gov.Provider-level Medicare Part B utilization and payment data.
- 2.NPPES NPI Registry. CMS.gov.National Provider Identifier registry used for provider enumeration and taxonomy metadata.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.